Management of Cervical Spine Chordomas. Case Report KU LeuvenBart Depreitere, Vincent Vander Poorten, Jan Vranckx, Joannes Menten
Integration of DC vaccination in the primary treatment of adults with glioblastoma: final results of the HGG-2006 phase I/II trial KU LeuvenHilko Ardon, Stefaan Van Gool, W Maes, Steven De Vleeschouwer, et al.
Myeloid-derived suppressor cells: another hurdle for glioblastoma immunotherapy KU LeuvenWim Maes, Hilko Ardon, Marc Van Haaren, Steven De Vleeschouwer, et al.
INTRINSIC GENE EXPRESSION PROFILES OF GLIOMAS ARE A BETTER PREDICTOR OF SURVIVAL THAN HISTOLOGY KU LeuvenLonneke Gravendeel, Mathilde Kouwenhoven, Olivier Gevaert, Johan de Rooi, Andrew Stubbs, J Duijm, Anneleen Daemen, Fonnet Bleeker, Linda BC Bralten, Nanne Kloosterhof, et al.
Validation of RPA classification as a prognostic tool in adult patients with relapsed high-grade glioma vaccinated at time of recurrence KU LeuvenSteven De Vleeschouwer, Hilko Ardon, Frank Van Calenbergh
Abstracts from the 2009 Joint Meeting of the Society for Neuro-Oncology (SNO) and the American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Section on Tumors: October 22–24, 2009: New Orleans, LA KU LeuvenSteven De Vleeschouwer
Integration of DC vaccination in the primary treatment of adults with GBM: update of the HGG-2006 phase I/II trial KU LeuvenHilko Ardon, Stefaan Van Gool, Wim Maes, Steven De Vleeschouwer, et al.
Abstracts for the Thirteenth Annual Meeting of the Society for Neuro-Oncology: November 20–23, 2008 KU LeuvenSteven De Vleeschouwer
Integration of DC vaccination in the primary treatment of adults with GBM: update of the HGG-2006 phase I/II trial KU LeuvenStefaan Van Gool, Hilko Ardon, Wim Maes, Isabel Lopes, Stefan Rutkowski, Eckhart Kaempgen, Christof Kramm, Johannes Wolff, Frank Van Calenbergh, Steven De Vleeschouwer, et al.